Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for amelioration/prevention of adverse side effect in steroid therapy

A composition and steroid technology, applied in the new use of branched-chain amino acids, the composition for inhibiting the expression of muscle atrophy-related genes, the combined use of the composition and steroid drugs, to prevent bedridden, shorten the hospitalization period and treat period, the effect of preventing recession

Inactive Publication Date: 2013-05-29
EA PHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, unknown branched-chain amino acids (for example, leucine, etc.) inhibit the expression of muscle atrophy genes (atrogin-1 and MuRF-1) whose expression increases due to muscle atrophy-inducing stimuli

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for amelioration/prevention of adverse side effect in steroid therapy
  • Composition for amelioration/prevention of adverse side effect in steroid therapy
  • Composition for amelioration/prevention of adverse side effect in steroid therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0144] (Example 1) Muscular atrophy preventive effect of BCAA in dexamethasone-administered rats

[0145] Dexamethasone (600 μg / kg) was administered intraperitoneally to rats (SD; 10-11 weeks old) for 5 consecutive days. The isoleucine, leucine and valine (weight ratio 1:2:1.2) blend (BCAA) administration group was simultaneously orally administered with 0.75 g / kg of the above BCAA for 5 consecutive days. The vehicle group was sequentially administered orally with distilled water in the same manner.

[0146] On day 5, rats were necropsied and analyzed for functional assessment of muscle strength, blood glucose levels and plasma insulin levels using food intake, body weight profile, muscle weight, grip strength measurement devices.

[0147] As a control group, normal rats reared in pairs were used.

[0148] By comparison with the vehicle group, the BCAA administration group showed inhibition of body weight loss and reduction in food intake ( figure 1 ). The decrease in musc...

Embodiment 2

[0149] (Example 2) Muscle atrophy therapeutic effect of BCAA in rats administered with dexamethasone

[0150] Dexamethasone (600 μg / kg) was administered intraperitoneally to rats (SD; 10-11 weeks old) for 5 consecutive days to induce muscle atrophy. On the 6th and 7th days from the end of the dexamethasone administration, BCAA (0.75 g / kg) was orally administered, and the therapeutic effect on muscle atrophy was examined. The vehicle group was sequentially administered orally with distilled water in the same manner.

[0151] On days 6 and 7, rats were necropsied and analyzed for muscle weight. R1 and R2 are days 1 and 2, respectively, of the recovery period (recovery; R), and correspond to days 6 and 7 from the end of dexamethasone administration.

[0152] By comparison with the vehicle group, the BCAA administration group showed early recovery of muscle weight ( Figure 6 ).

Embodiment 3

[0153] (Example 3) Osteoporosis preventive effect of BCAA in dexamethasone-administered rats

[0154] Dexamethasone (600 μg / kg) was administered intraperitoneally to rats (SD; 10-11 weeks old) for 1.5 consecutive months. The isoleucine, leucine and valine (weight ratio 9:7:6) blend (BCAA) administration group was simultaneously orally administered with 0.75 g / kg of the above BCAA for 1.5 consecutive months. The vehicle group was sequentially administered orally with distilled water in the same manner.

[0155] At 1.5 months, rats were necropsied and analyzed for plasma ALP levels. It is known that plasma ALP shows a high value when bone metabolic turnover is high.

[0156] By comparison with the vehicle group, the BCAA administration group showed low plasma ALP values ​​( Figure 7 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a composition containing isoleucine, leucine and valine as active ingredients for improving or suppressing side effects associated with a steroid treatment and a composition for suppressing muscular atrophy-related gene. The composition improves or suppresses side effects in a steroid treatment such as muscular atrophy, muscular pain, arthritic pain, impaired glucose tolerance, decreased bone metabolism, impaired immunity, loss of appetite, body weight loss, fatigability and the like, and further suppresses muscular atrophy associated with various diseases. In addition, the composition suppresses muscular atrophy associated with promoted expression of muscular atrophy-related gene associated with glucocorticoid excess or renal failure pathology and the like. Therefore, the composition is effective for improving the QOL of patients.

Description

[0001] The application date is December 12, 2007, the international application number is PCT / JP2007 / 073954, the application number entering the national phase is 200780051135.9, and the invention name is "combination for improving / preventing adverse side effects in steroid therapy Divisional application of the PCT application for "things". technical field [0002] The present invention relates to a composition for improving or suppressing side effects in steroid therapy, a composition for inhibiting muscle atrophy-related gene expression, and the combined use of the composition and steroid drugs. More specifically, the present invention relates to novel uses of branched chain amino acids. Background technique [0003] Symptomatic treatment of side effects in steroid therapy currently includes (1) infections: administration of antibacterial agents, (2) diabetes: administration of insulin and oral antidiabetics, (3) gastrointestinal symptoms: antacids and H2 blockade (4) ost...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61P21/00A61P29/00A61P19/02A61P3/00A61P37/02A61P13/12A23L1/305
CPCA23L1/3051A61K31/198A23L33/175A61P1/14A61P3/00A61P3/08A61P13/12A61P19/00A61P19/02A61P19/08A61P21/00A61P29/00A61P37/02A61P37/04A61P43/00
Inventor 西谷忍竹鼻健司
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com